Abstract 5911: The role of CD53+ subsets and the JAK/STAT3 pathway in regulating cancer stemness and immune escape in esophageal squamous cell carcinoma

T cell therapy has revolutionized treatment for hematologic malignancies but faces significant challenges in solid tumor applications, including esophageal squamous cell carcinoma (ESCC). In this study, we utilized a dynamic subcutaneous tumor growth model in mice to investigate how ESCC tumors modulate T cell activity through four distinct phases: initial enlargement, reduction, stabilization, and explosive growth. Single-cell sequencing revealed that CD53+ subsets were enriched in the reduction stage and showed their function in stemness regulation and immune escape. Functionally, CD53+ mouse ESCC cell lines showed a higher organoid formation ability when compared with CD53- cells. When co-cultured with T cells, CD53+ ESCC cell lines revealed their capability in regulating T cell exhaustion. Mechanically, GO enrichment analysis and western blotting demonstrated that CD53+ cells activated IL-6/JAK/STAT3 signaling pathways and upregulated their downstream genes such as C-myc and PD-L1. Furthermore, in vivo study showed that JAK inhibitor Ruxolitinib and STAT3 inhibitor C188-9 could efficiently reduce tumor growth and enhance T cell infiltration in CD53+ mouse ESCC cell lines, suggesting a role in tumor proliferation and T cell editing. This study aims to elucidate the biological function of CD53+ subset ESCC cells in tumor progression and verify their role in T cell regulation, offering new therapeutic targets for ESCC treatment. Citation Format: Beilei Liu, Hongyu Zhou, Licheng Tan, Bowen Yao, Shuang Zhang, Jiayi Huang, Mengsu Yang, Xinyuan Guan. The role of CD53+ subsets and the JAK/STAT3 pathway in regulating cancer stemness and immune escape in esophageal squamous cell carcinoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 5911.

Authors

Institutions

Publication Details

Journal
Cancer Research
Published
2025-04-21
DOI
https://doi.org/10.1158/1538-7445.am2025-5911
Primary Topic
Cancer Cells and Metastasis
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Abstract 5911: The role of CD53+ subsets and the JAK/STAT3 pathway in regulating cancer stemness and immune escape in esophageal squamous cell carcinoma

Jiayi Huang, Licheng Tan, Shuang Zhang, Mengsu Yang et al.
Cancer Research
Cancer Cells and Metastasis
article

Abstract 5911: The role of CD53+ subsets and the JAK/STAT3 pathway in regulating cancer stemness and immune escape in esophageal squamous cell carcinoma

Jiayi Huang, Licheng Tan, Shuang Zhang, Mengsu Yang, Hongyu Zhou, Xin‐Yuan Guan, Bowen Yao, Beilei Liu
article en

Abstract

T cell therapy has revolutionized treatment for hematologic malignancies but faces significant challenges in solid tumor applications, including esophageal squamous cell carcinoma (ESCC). In this study, we utilized a dynamic subcutaneous tumor growth model in mice to investigate how ESCC tumors modulate T cell activity through four distinct phases: initial enlargement, reduction, stabilization, and explosive growth. Single-cell sequencing revealed that CD53+ subsets were enriched in the reduction stage and showed their function in stemness regulation and immune escape. Functionally, CD53+ mouse ESCC cell lines showed a higher organoid formation ability when compared with CD53- cells. When co-cultured with T cells, CD53+ ESCC cell lines revealed their capability in regulating T cell exhaustion. Mechanically, GO enrichment analysis and western blotting demonstrated that CD53+ cells activated IL-6/JAK/STAT3 signaling pathways and upregulated their downstream genes such as C-myc and PD-L1. Furthermore, in vivo study showed that JAK inhibitor Ruxolitinib and STAT3 inhibitor C188-9 could efficiently reduce tumor growth and enhance T cell infiltration in CD53+ mouse ESCC cell lines, suggesting a role in tumor proliferation and T cell editing. This study aims to elucidate the biological function of CD53+ subset ESCC cells in tumor progression and verify their role in T cell regulation, offering new therapeutic targets for ESCC treatment. Citation Format: Beilei Liu, Hongyu Zhou, Licheng Tan, Bowen Yao, Shuang Zhang, Jiayi Huang, Mengsu Yang, Xinyuan Guan. The role of CD53+ subsets and the JAK/STAT3 pathway in regulating cancer stemness and immune escape in esophageal squamous cell carcinoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 5911.

Cancer ResearchVol. 85(8_Supplement_1)
City University of Hong Kong (HK), University of Hong Kong (HK)
Openalex Percentile: Top 88%
Cancer Cells and Metastasis
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.